Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
Johnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms. Analysts say the potential drugs are long shots.
Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.
For more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward the drugmaker’s diabetes portfolio.
The agent, called Amyvid, is not expected to produce high-dollar sales for Lilly, but it could help to identify patients with Alzheimer’s—and those without it—earlier, perhaps improving treatment and focusing research efforts.
Eli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s experimental Alzheimer’s drug could double the share price.
American Senior Communities says Auguste's Cottage at Harrison Terrace on the east side of Indianapolis already has 90 residents.
Analysts have eyes on trial data for drug that could be a game-changer for the company.
Remaining grant money will be invested to beef up the infrastructure of the Indiana Network for Patient Care, a health information exchange operated by the Indianapolis-based Regenstrief Institute.
Eli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted.